196 related articles for article (PubMed ID: 24727854)
1. Clinical utility of 18F-FDG positron emission tomography in malignant peritoneal mesothelioma.
Domènech-Vilardell A; Rasiej MJ; Taub RN; Ichise M
Q J Nucl Med Mol Imaging; 2016 Mar; 60(1):54-61. PubMed ID: 24727854
[TBL] [Abstract][Full Text] [Related]
2. FDG PET/CT patterns of treatment failure of malignant pleural mesothelioma: relationship to histologic type, treatment algorithm, and survival.
Gerbaudo VH; Mamede M; Trotman-Dickenson B; Hatabu H; Sugarbaker DJ
Eur J Nucl Med Mol Imaging; 2011 May; 38(5):810-21. PubMed ID: 21210110
[TBL] [Abstract][Full Text] [Related]
3. Prognostic value of SUVmax on 18F-fluorodeoxyglucose PET/CT scan in patients with malignant pleural mesothelioma.
Lim JH; Choi JY; Im Y; Yoo H; Jhun BW; Jeong BH; Park HY; Lee K; Kim H; Kwon OJ; Han J; Ahn MJ; Kim J; Um SW
PLoS One; 2020; 15(2):e0229299. PubMed ID: 32069313
[TBL] [Abstract][Full Text] [Related]
4. Clinical implications of 18F-fluorodeoxyglucose positron emission tomography/computed tomography at delayed phase for diagnosis and prognosis of malignant pleural mesothelioma.
Abe Y; Tamura K; Sakata I; Ishida J; Ozeki Y; Tamura A; Uematsu K; Sakai H; Goya T; Kanazawa M; Machida K
Oncol Rep; 2012 Feb; 27(2):333-8. PubMed ID: 22024889
[TBL] [Abstract][Full Text] [Related]
5. 18F-FDG Uptake of Localized Malignant Peritoneal Mesothelioma.
Kodama E; Kodama T; Ichikawa T; Ikoma H; Hashimoto J
Clin Nucl Med; 2020 Feb; 45(2):161-163. PubMed ID: 31876833
[TBL] [Abstract][Full Text] [Related]
6. Is FDG-PET/CT useful for managing malignant pleural mesothelioma?
Otsuka H; Terazawa K; Morita N; Otomi Y; Yamashita K; Nishitani H
J Med Invest; 2009 Feb; 56(1-2):16-20. PubMed ID: 19262009
[TBL] [Abstract][Full Text] [Related]
7. A Case of Localized Malignant Peritoneal Mesothelioma Evaluated by 18F-FDG PET/CT.
Xu T; Hu J; Zhang X; Cao J; Chen Y
Clin Nucl Med; 2020 Nov; 45(11):890-891. PubMed ID: 32604114
[TBL] [Abstract][Full Text] [Related]
8.
Elliott HS; Metser U; de Perrot M; Cho J; Bradbury P; Veit-Haibach P; Hussey D; Noam T
Br J Radiol; 2018 Jun; 91(1086):20170814. PubMed ID: 29498536
[TBL] [Abstract][Full Text] [Related]
9.
Niccoli Asabella A; Di Palo A; Altini C; Fanelli M; Ferrari C; Lavelli V; Ranieri G; Gadaleta CD; Rubini G
Hell J Nucl Med; 2018; 21(3):191-197. PubMed ID: 30411729
[TBL] [Abstract][Full Text] [Related]
10. Does positron emission tomography offer prognostic information in malignant pleural mesothelioma?
Sharif S; Zahid I; Routledge T; Scarci M
Interact Cardiovasc Thorac Surg; 2011 May; 12(5):806-11. PubMed ID: 21266493
[TBL] [Abstract][Full Text] [Related]
11. The association of 18F-FDG PET/CT parameters with survival in malignant pleural mesothelioma.
Klabatsa A; Chicklore S; Barrington SF; Goh V; Lang-Lazdunski L; Cook GJ
Eur J Nucl Med Mol Imaging; 2014 Feb; 41(2):276-82. PubMed ID: 24057459
[TBL] [Abstract][Full Text] [Related]
12. FDG PET-derived parameters as prognostic tool in progressive malignant pleural mesothelioma treated patients.
Incerti E; Broggi S; Fodor A; Cuzzocrea M; Samanes Gajate AM; Mapelli P; Fiorino C; Dell'Oca I; Pasetti M; Cattaneo M; Calandrino R; Gianolli L; Di Muzio N; Picchio M
Eur J Nucl Med Mol Imaging; 2018 Nov; 45(12):2071-2078. PubMed ID: 29876617
[TBL] [Abstract][Full Text] [Related]
13. Prognostic value of pretreatment volume-based quantitative
Kitajima K; Doi H; Kuribayashi K; Hashimoto M; Tsuchitani T; Tanooka M; Fukushima K; Nakano T; Hasegawa S; Hirota S
Eur J Radiol; 2017 Jan; 86():176-183. PubMed ID: 28027744
[TBL] [Abstract][Full Text] [Related]
14. Potential of dual time point FDG-PET imaging in differentiating malignant from benign pleural disease.
Mavi A; Basu S; Cermik TF; Urhan M; Bathaii M; Thiruvenkatasamy D; Houseni M; Dadparvar S; Alavi A
Mol Imaging Biol; 2009; 11(5):369-78. PubMed ID: 19472014
[TBL] [Abstract][Full Text] [Related]
15. 18F-FDG PET/CT for the prediction and detection of local recurrence after radiofrequency ablation of malignant lung lesions.
Singnurkar A; Solomon SB; Gönen M; Larson SM; Schöder H
J Nucl Med; 2010 Dec; 51(12):1833-40. PubMed ID: 21078787
[TBL] [Abstract][Full Text] [Related]
16. Clinical value of fluorodeoxyglucose-positron emission tomography/computed tomography in differentiation of malignant mesothelioma from asbestos-related benign pleural disease: an observational pilot study.
Yildirim H; Metintas M; Entok E; Ak G; Ak I; Dundar E; Erginel S
J Thorac Oncol; 2009 Dec; 4(12):1480-4. PubMed ID: 19875971
[TBL] [Abstract][Full Text] [Related]
17. Whole-Body MRI: Comparison of Its Capability for TNM Staging of Malignant Pleural Mesothelioma With That of Coregistered PET/MRI, Integrated FDG PET/CT, and Conventional Imaging.
Ohno Y; Yui M; Aoyagi K; Kishida Y; Seki S; Koyama H; Yoshikawa T
AJR Am J Roentgenol; 2019 Feb; 212(2):311-319. PubMed ID: 30512992
[TBL] [Abstract][Full Text] [Related]
18. Patterns of disease progression on 18F-fluorodeoxyglucose positron emission tomography-computed tomography in patients with malignant pleural mesothelioma undergoing multimodality therapy with pleurectomy/decortication.
Bille A; Chicklore S; Okiror L; Cook GJ; Spicer J; Landau D; Lang-Lazdunski L
Nucl Med Commun; 2013 Nov; 34(11):1075-83. PubMed ID: 23963351
[TBL] [Abstract][Full Text] [Related]
19. Dual time point FDG PET for evaluation of malignant pleural mesothelioma.
Yamamoto Y; Kameyama R; Togami T; Kimura N; Ishikawa S; Yamamoto Y; Nishiyama Y
Nucl Med Commun; 2009 Jan; 30(1):25-9. PubMed ID: 19306511
[TBL] [Abstract][Full Text] [Related]
20. Prognostic value of 18F-FDG standard uptake value by integrated PET/CT in the staging of malignant pleural mesothelioma.
Genestreti G; Moretti A; Piciucchi S; Tiseo M; Bersanelli M; Scarlattei M; Scarpi E; Dubini A; Matteucci F; Sanna S
Technol Cancer Res Treat; 2012 Apr; 11(2):163-7. PubMed ID: 22335410
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
